$5995 | Single User
$8995 | Global License

Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
[Lowest Price Guaranteed: $5,995]

Published by FirstWord Pharma: 01 Feb 2015 | 196 | In Stock
Related Topics: Enbrel , Humira , Internet , Medical , Pfizer

Introduction

Introduction


Based on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal antibodies (mAbs) can best meet physician needs on various supporting roles. In addition, gain comparative insights on the Medical Affairs teams’ roles from the originator anti-TNF companies.


Using Need-Gap analysis, a proprietary analytics tool to FirstWord, areas of unmet need are identified, which provide valuable guidance on opportunities for corporate and brand positioning, and communication.


With the launch of biosimilar Remicade, and anti-TNF mAb, currently taking place across the major markets of Europe – France, Germany, Italy, Spain, the UK; EU5 – biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs’ strategy for their products. Refining performance through smarter delivery, higher quality interaction, and effective communication with rheumatologists, dermatologists and gastroenterologists becomes vital for ensuring optimal performance levels of Medical Affairs teams.


Puchase Reasons


Key Benefits


  • Review analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists’ interactions with Medical Affairs teams highlighting good and bad performance, and identifying key areas for improvement

  • Gain detailed insights on how Medical Affairs teams from originator and biosimilar anti-TNF companies can improve physician satisfaction across a range of key performance attributes

  • Understand the key areas physicians prefer to interact with Medical Affairs Teams from the originator and biosimilar anti-TNF companies

  • Identify usage of 5 originator anti-TNFs, and which products are prescribed most

  • Learn what physicians believe are the most, and least, important attributes of Medical Affairs team engagement, and how these rate across originator and biosimilar anti-TNF companies

  • Gain insights on how Medical Affairs teams can provide better service to physicians

  • Key Features


    Filled with charts and up-to-the-minute survey analysis, this report offers:


  • Precise and timely analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists’ interactions with Medical Affairs teams highlighting good and bad performance and identifying key areas for improvement

  • Examination of physicians' current touch points with Medical Affairs teams

  • Key findings regarding the attributes of Medical Affairs teams physicians value most and least

  • Detailed data broken down by each EU5 country

  • Need-Gap analysis, a proprietary analytics tool to FirstWord, identifies current unmet needs

  • Top Takeaways


  • Insights on the current status of support and interactions with Medical Affairs teams from the originator anti-TNF companies and biosimilar anti-TNF companies

  • Expectations of support and interactions with Medical Affairs teams from biosimilar anti-TNF companies

  • Preferred contact frequency, form and other needs from the biosimilar anti-TNF companies

  • About the Survey


    What is Need-Gap Analysis?


    This report includes slides that provide Need-Gap analysis, a proprietary analytics tool that identifies areas of unmet need which provide valuable guidance on opportunities for corporate and brand positioning, and communication.


    keyfacts.jpgInterviewing Methodology


    Data was collected via a 15-minute Internet-based questionnaire.


    sampledis.jpgSample Distribution


    150 rheumatologists, dermatologists, and gastroenterologists in France, Germany, Spain, Italy and the UK.


    Screening Criteria


  • See at least 20 patients in total in a typical month

  • Have been in active practice between 3-35 years

  • Devote at least 50% of time to direct patient care

  • Prescribed at least one of the listed originator anti-TNFs

  • Have had an interaction with Medical Affairs teams from at least one of the originator anti-TNF companies in the past 6 months

  • Originator Anti-TNFs Included in Survey


  • Cimzia (certolizumab pegol; UCB)

  • Enbrel (etanercept; Amgen/Pfizer)

  • Humira (adalimumab; AbbVie)

  • Simponi (golimumab; Merck & Co.)

  • Remicade (infliximab; Janssen Biotech/Merck & Co.)

  • About FirstWord Reports


    FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.


  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

  • Learn more at www.firstwordgroup.com.

    Table of Contents
    for Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    196 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Medical Affairs Reputations (US): Multiple Sclerosis
    IntroductionCompare how well pharma Medical Affairs teams perform and find out which ones physicians...
    01 Jul 2015 by FirstWord Pharma USD $5,995 More Info
    Building Strong Cross-Functional Medical Affairs Teams
    IntroductionCould your Medical Affairs team be better integrated for more effective cross-functional...
    01 May 2015 by FirstWord Pharma USD $695 More Info
    Physician Views: How do endocrinologists value diabetes-focused medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    08 Dec 2014 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies
    IntroductionAs the cancer drug market continues to face significant challenges in an environment of ...
    02 Dec 2014 by FirstWord Pharma USD $3,900 More Info
    Reshaping Medical Affairs: delivering value to KOLs and payers
    IntroductionHistorically, the key role of Medical Affairs was supporting the initial regulatory appr...
    21 Aug 2014 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies
    IntroductionAs the oncology drug market continues to face significant road bumps in terms of develop...
    14 Aug 2014 by FirstWord Pharma USD $3,900 More Info
    Physician Views: How do pulmonologists value medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    09 Jul 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    18 Jun 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: How do oncologists value medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    22 May 2014 by FirstWord Pharma USD $695 More Info
    Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value
    IntroductionIn this era of transparency, Medical Affairs is rapidly becoming the new voice of Pharma...
    01 May 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...